GGHC
PRCT icon

Gilder Gagnon Howe & Co’s Procept Biorobotics PRCT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,087
Closed -$2.16M – 251
2025
Q1 		$2.16M Sell
37,087
-735
-2% -$50.2K 0.03% 167
2024
Q4 		$3.05M Buy
+37,822
New +$3.23M 0.03% 171
2021
Q4 		– Sell
-123,572
Closed -$4.71M – 419
2021
Q3 		$4.71M Buy
+123,572
New +$4.74M 0.02% 249

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Gilder Gagnon Howe & Co's PRCT Position: Q2 2025 in Review

Gilder Gagnon Howe & Co sold out of Procept Biorobotics (PRCT) in Q2 2025, closing a stake of 37,087 shares — an estimated $2.16M sold.

Gilder Gagnon Howe & Co first reported a position in PRCT in Q3 2021 and held it in 3 quarters. The position peaked at $4.71M in Q3 2021. 271 funds tracked by Wall St. Rank hold PRCT as of Q2 2025.

  • Gilder Gagnon Howe & Co reported no remaining Procept Biorobotics position as of Q2 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 37,087 Procept Biorobotics shares in Q2 2025, an estimated $2.16M.
  • Gilder Gagnon Howe & Co first reported a position in Procept Biorobotics in Q3 2021 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Procept Biorobotics position peaked at $4.71M in Q3 2021.
  • 271 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2025, filed 14 Aug 2025.